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Introduction
The devastating effect of the AIDS epidemic is still a reality. However, since the highly active antiretroviral therapy (HAART) has been employed to combat the illness, HIV infection has definitely become more manageable. 1 During the last 20 years an unprecedented success has been achieved in discovering anti-HIV drugs as reflected by the fact that there are now more drugs approved for the treatment of HIV than for all other viral infections taken together.
The currently FDA approved anti-HIV drugs can be divided into seven groups: nucleoside reverse transcriptase inhibitors, nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors (PIs), fusion inhibitors, co-receptor inhibitors, and integrase inhibitors. 2 Detailed knowledge of the structure of HIV protease and its substrate has led to the preparation of specific PIs, whose arrival was a pivotal moment in the development of antiretroviral therapy and made possible the dual class triple combination therapy. 3 Despite the already marketed PIs have an evident crucial role into HAART regimen, their clinical utility can be limited by low bioavailability and reduced long-term viral inhibition, with multiple protease resistance mutations being observed. Thus, novel PIs with high potency against the known HIV protease variants have been designed. We recently demonstrated the beneficial effect of a heteroaromatic group in a series of new thienyl ring containing analogues of nelfinavir and saquinavir, which showed to maintain or even increase their activity against either wild type or mutant HIV protease. 4 Recently the concept of targeting the protein backbone in structure-based 
Results and discussion
Although the synthetic work can appear tedious at a first sight, we took advantage of the commercially available bidentate electrophile (S)-glycidol 1 for the generation of the core (scheme 1). The glycidol was first activated by the reaction with m-nosyl chloride to obtain compound 2.
The subsequent nucleophilic displacement of the nosyl group was performed by the commercially available 4-, 5-, or 6-hydroxyindoles affording the corresponding oxyindoles 3, 4 and 5 in good yields and mild reaction conditions, without any competitive epoxide ring opening. 8 Each oxyindole represents the common precursor for the preparation of either perhydroisoquinyl-or sulfonamidyl derivatives. Indeed, perhydroisoquinoline (PHIQ) was introduced by direct regioselective oxiranyl ring opening, obtaining the corresponding 6, 7 and 8 in good yield and as single diastereoisomers (> 57% overall yield in 3 steps). 
Scheme 1
For the preparation of arylsulfonamidyl compounds, the oxiranyl-oxyindoles 3, 4 and 5 were reacted with isobutylamine, affording the amino-derivatives 9, 10 and 11 in excellent yield.
Starting from this triad, arylsulfonyl fragments with different electronic properties were introduced by employing suitable chlorides, affording compounds 12a,b, 13a,b and 14a,b (> 46% overall yield in 4 steps). In particular, electron releasing 3,4-dimethoxyphenyl-and electron withdrawing 4-nitrophenyl groups were introduced to evaluate their potentially different effect on inhibitory activity. Compound 13a was also transformed into 4-aminophenyl derivative 13c by Pdcatalyzed hydrogenation.
All these oxyindoles were tested in vitro for anti HIV-PR activity and the results are reported in Table 1 . 
Scheme 2
Then the suitable arylsulfonyl moiety was introduced, namely 4-nitro-and 3,4-dimethoxyphenylsulfonyl groups, in high yield giving 18a and 18b. After regioselective tosylation of primary hydroxyl group, the two epoxides 19a and 19b were alternatively prepared, and they were finally opened with 4-and 5-aminoindoles, affording the four new derivatives 22a,b and 23a,b (> 41% overall yield in 5 steps). In vitro tests of these aminoindolyl compounds against wild type HIV-1 PR are reported in Table 2 . 
These results pointed out the general negative effect of amino group on the inhibition activity of indole derivatives, whatever the position of the nitrogen on the heterocycle. The introduction of sulfonamidyl groups instead of PHIQ even reduced the activity of the resulting compounds.
Finally, we wanted to investigate the effect of carbamoyl moiety, instead of amino group, considering its beneficial effect in certain non peptidic inhibitors, as Darunavir.
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The preparation of the corresponding carbamoyl derivatives of 4-and 5-indoles was straightforward. 4-and 5-aminoindoles 20 and 21 were first reacted with pnitrophenylchlorocarbonate, to afford the activated carbamates 24 and 25 (scheme 3). Glycidol was then introduced by substitution reaction, and the common intermediates oxiranyl carbamates 
Scheme 3
These intermediates were alternatively transformed into PHIQ derivatives 28, 29 (> 67% overall yield in 3 steps) and sulfonamides 32a,b, 33a,b,c (> 63% overall yield in 4 steps) by oxiranyl ring opening with PHIQ and iso-butylamine followed by sulfonylation, respectively.
All these carbamates were tested and their inhibition activities are listed in Table 3 . Table 3 Regioisomer PHIQ (IC 50 , µM)
Although the general positive effect on the activity of the substitution of amino group with carbamoyl one, usually ranging in the micromolar values, the results appear difficult to rationalize.
PHIQ moiety contributes better on 4-indole derivative, whether arylsulphonamide group matches with 5-indole one. Such a structure is very sensitive to the overall length of the molecule, depending on the linkage between the indole ring and the core of the inhibitor, and requires a careful selection of the substituents on the aryl system. Thus, the 3,4-dimethoxy aryl system is favourable in compounds as 13b, but fails entirely in the corresponding carbamate 33b, with an extremely high IC 50 of 1.4 mM. Conversely, the nitroaryl system is effective in both the series of The nitro-(13a) or one of the two methoxy-groups (13b, Figure 3b ) could establish favourable hydrogen bonding with the backbone amide proton of Asp30'. However, the second methoxygroup in the larger 33b structure, clearly leads to unfavourable steric clash (Figure 3c ). This prompted us to remove such a group as in 33c (Figure 3c ), and this led to a three orders of magnitude gain in activity (see Table 3 ).
Conclusion
In conclusion, our systematic study confirmed the possibility of introducing indole ring in anti-HIV-1 PR inhibitors which are active in the micromolar range. Although the net contribution of the individual substituents cannot be fully rationalized, the following general insights may be found: a) oxyindoles and carbamoyl indoles showed general good activity, whereas simple aminoindoles are much less active, b) 5-substituted indoles appear to be the best regioisomers, apparently they fit better into the S 1 or S 2 site of the enzyme, depending on the linker length and distance from the core, 2, 127.1, 120.5, 117.6, 112.3, 103.4, 102.7, 70.5, 50.9, 44.3 
(-)-(R)-6-Oxiranylmethoxy-1H-indole (5)
Compound 5 was isolated as a yellow solid (0.036 g, 61% H, 8.72; N, 9.83. Found: C, 70.20; H, 8.73 ; N, 9.80. 9, 152.9, 131.3, 128.2, 125.1, 112.6, 111.8, 103.7, 102.7, 71.2, 70.3, 68.3, 59.4, 58.6, 50.7, 35.7, 35.7, 33.1, 30.8, 30.6, 29.6, 28.6, 26.1, 25.7, 20. : C, 70.22; H, 8.72; N, 9.83. Found: C, 70.19; H, 8.76 ; N, 9.85.
(-)-(3S,4aS,8aS)-2-[(2R)-Hydroxy-3-(1H-indol-6-yloxy)-propyl]-decahydro-isoquinoline-3-carboxylic acid tert-butylamide (8)
Compound 8 155.0, 136.4, 123.4, 122.5, 121.1, 110.1, 102.1, 95.9, 70.9, 70.2, 68.3, 59.5, 58.5, 50.7, 35.7, 33.1, 30.8, 30.6, 28.6, 26.1, 25.7, 20.5 H, 8.72; N, 9.83. Found: C, 70.20; H, 8.71 ; N, 9.86.
(-)-(3S,4aS,8aS)-(1H-Indol-4-yl)-carbamic acid 3-(3-tert-butylcarbamoyl-octahydro-isoquinolin-2-yl)-(2R)-hydroxy-propyl ester (28)
Compound 28 7, 138.6, 136.7, 129.7, 128.1, 125.2, 115.7, 111.3, 106.4, 102.6, 70.1, 68.1, 59.4, 58.8, 55.7, 50.8, 35.7, 33.0, 31.9, 30.7, 30.6, 29.7, 29.3, 25.7 . IR (cm 7, 154.4, 133.1, 130.0, 129.7, 128.1, 125.2, 115.7, 111.3, 102.6, 70.1, 68.1, 59.4, 58.8, 50.8, 35.7, 33.0, 31.9, 30.7, 30.6, 29.7, 29.3, 28.7, 26.1, 25.7, 20.6. IR (cm -1 ) 3410, 3280, 3046, 2939 , 1730 , 1642 , 1308 , 1245 , 1128 H, 8.14; N, 11.91. Found: C, 66.39; H, 7.15; N, 11.93 .
Ring opening of the epoxides with iso-butylamine: general procedure i-ButNH 2 (1.12 g, 1.48 mmol) was added to a stirred solution of suitable epoxide (1.38 mmol) in iPrOH (30 mL) at room temperature for 26 h. Then the solvent was removed under reduced pressure. The crudes of compounds 11, 17 and 30 were used in the subsequent reaction without any purification. Compounds 9, 10 and 31 were purified by column chromatography on silica gel.
Compound 9 was obtained as a colourless thick oil (0.400 g, 99% 2, 128.2, 125.1, 112.4, 111.7, 103.6, 101.9, 71.3, 67.9, 57.4, 51.8, 27.7, 20.4. IR (cm -1 ) 3402, 3313, 3050, 2958 , 1455 , 1159 H, 8.45; N, 10.68. Found: C, 68.69; H, 8.43; N, 10.72 .
Compound 10 152. 9, 131.2, 128.2, 125.1, 112.4, 111.7, 103.6, 101.9, 71.3, 67.9, 57.4, 51.8, 27.7, 20.4. IR (cm -1 ) 3402, 3313, 3050, 2958 , 1455 , 1159 H, 8.45; N, 10.68. Found: C, 68.69; H, 8.43; N, 10.64 . 4, 133.0, 130.1, 128.0, 125.3, 125.1, 115.5, 111.3, 102.6, 67.9, 67.2, 57.6, 51.3, 28.3, 20.5. IR (cm -1 ) 3316, 2958 , 1704 , 1557 , 1481 , 1237 , 1063 H, 7.59; N, 13.76. Found: C, 62.89; H, 7.55; N, 13.68 .
Synthesis of arylsulfonamides: general procedure
Dry triethylamine (0.14 mL, 151. 3, 149.1, 145.8, 133.3, 128.4, 128.2, 124.5, 124.2, 119.3, 107.8, 102.6, 98.5, 74.2, 65.3, 57.7, 52.2, 25.7, 20.9 H, 5.63; N, 9.39; S, 7.17. Found: C, 56.38; H, 5.61; N, 9.35; S, 7.20 .
Compound 12b 1, 148.5, 132.9, 129.1, 128.4, 124.1, 118.5, 118.2, 115.8, 112.4, 107.5, 102.5, 99.0, 74.1, 66.7, 57.1, 56.2, 55.3, 26.5, 20.9 . IR (cm -1 ) 3421, 3118, 2954, 1565, 1320, 1148. 
